WO2005098435A3 - Peptides and peptidomimetics binding to cd23 - Google Patents

Peptides and peptidomimetics binding to cd23 Download PDF

Info

Publication number
WO2005098435A3
WO2005098435A3 PCT/IB2005/001133 IB2005001133W WO2005098435A3 WO 2005098435 A3 WO2005098435 A3 WO 2005098435A3 IB 2005001133 W IB2005001133 W IB 2005001133W WO 2005098435 A3 WO2005098435 A3 WO 2005098435A3
Authority
WO
WIPO (PCT)
Prior art keywords
ala
asn
phe
gly
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001133
Other languages
French (fr)
Other versions
WO2005098435A2 (en
Inventor
Mohammad Djavad Mossalayi
Daniel Moynet
Philippe Vincendeau
Jerome Rambert
Christopher R Self
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Victor Segalen Bordeaux 2
Original Assignee
Universite Victor Segalen Bordeaux 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Victor Segalen Bordeaux 2 filed Critical Universite Victor Segalen Bordeaux 2
Priority to US10/594,674 priority Critical patent/US8071552B2/en
Priority to JP2007506867A priority patent/JP2007531536A/en
Priority to EP05718527A priority patent/EP1733231B1/en
Priority to AU2005229779A priority patent/AU2005229779A1/en
Priority to CA002560726A priority patent/CA2560726A1/en
Priority to AT05718527T priority patent/ATE508362T1/en
Priority to DE602005027830T priority patent/DE602005027830D1/en
Publication of WO2005098435A2 publication Critical patent/WO2005098435A2/en
Publication of WO2005098435A3 publication Critical patent/WO2005098435A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1-X2- X3-X4-X5-X6-X7-X8, wherein: X1 is Phe, or is absent; X2 is His or Ala; X3 is Glu, Ser, Ala, Asn, Lys, or Cys; X4 is Asn, Phe, Gln, Pro, Ser, or Ala; X5 is Trp; X6 is Pro, Arg, Glu, Gly, Cys, or Lys; X7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8 is Phe, Gly, or is absent.
PCT/IB2005/001133 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to cd23 Ceased WO2005098435A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/594,674 US8071552B2 (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to CD23
JP2007506867A JP2007531536A (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics that bind to CD23
EP05718527A EP1733231B1 (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to cd23
AU2005229779A AU2005229779A1 (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to CD23
CA002560726A CA2560726A1 (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to cd23
AT05718527T ATE508362T1 (en) 2004-04-05 2005-04-05 PEPTIDES AND PEPTIDE MIMETICS THAT BIND TO CD23
DE602005027830T DE602005027830D1 (en) 2004-04-05 2005-04-05 PEPTIDES AND PEPTIDE MIMETICS BINDING TO CD23

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290899.6 2004-04-05
EP04290899 2004-04-05

Publications (2)

Publication Number Publication Date
WO2005098435A2 WO2005098435A2 (en) 2005-10-20
WO2005098435A3 true WO2005098435A3 (en) 2006-03-30

Family

ID=34931020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001133 Ceased WO2005098435A2 (en) 2004-04-05 2005-04-05 Peptides and peptidomimetics binding to cd23

Country Status (8)

Country Link
US (1) US8071552B2 (en)
EP (1) EP1733231B1 (en)
JP (1) JP2007531536A (en)
AT (1) ATE508362T1 (en)
AU (1) AU2005229779A1 (en)
CA (1) CA2560726A1 (en)
DE (1) DE602005027830D1 (en)
WO (1) WO2005098435A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
DK1786784T3 (en) 2004-08-20 2011-02-14 Mannkind Corp Catalysis of diketopiperazine synthesis
CN104436170B (en) 2004-08-23 2018-02-23 曼金德公司 Diketopiperazine salt for drug delivery
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (en) 2006-02-22 2008-11-03 맨카인드 코포레이션 Method for Improving Pharmaceutical Properties of Microparticles Containing Diketopiperazine and Active Agents
CN100445296C (en) * 2006-03-31 2008-12-24 浙江大学 Polypeptide organic compound and application thereof in xenotransplantation
EP2082042A4 (en) * 2007-01-26 2010-08-18 Folia Biotech Inc Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp Dry powder inhaler and composition therefor
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX382244B (en) 2010-07-23 2025-03-13 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
KR102465025B1 (en) 2013-07-18 2022-11-09 맨카인드 코포레이션 Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US20170204140A1 (en) * 2014-07-23 2017-07-20 Deakin University Antagonistic peptides
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012741A1 (en) * 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
WO1998037099A1 (en) * 1997-02-20 1998-08-27 Idec Pharmaceuticals Corporation Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics
DE19749277A1 (en) * 1997-11-07 1999-05-20 Univ Leipzig Removing albumin from liquid by affinity chromatography, for purification of fluids or albulmin recovery
JP2002187899A (en) * 2000-12-19 2002-07-05 Canon Inc Peptides having binding properties to luciferase
WO2003064457A1 (en) * 2002-01-29 2003-08-07 Antisense Pharma Gmbh A method for inhibiting 'melanoma inhibitory activity' mia
WO2004026326A2 (en) * 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
CA2409287A1 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012741A1 (en) * 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
WO1998037099A1 (en) * 1997-02-20 1998-08-27 Idec Pharmaceuticals Corporation Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics
DE19749277A1 (en) * 1997-11-07 1999-05-20 Univ Leipzig Removing albumin from liquid by affinity chromatography, for purification of fluids or albulmin recovery
JP2002187899A (en) * 2000-12-19 2002-07-05 Canon Inc Peptides having binding properties to luciferase
WO2003064457A1 (en) * 2002-01-29 2003-08-07 Antisense Pharma Gmbh A method for inhibiting 'melanoma inhibitory activity' mia
WO2004026326A2 (en) * 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANNI H ET AL: "Selection of phage-display library peptides recognizing ethanol targets on proteins.", ALCOHOL (FAYETTEVILLE, N.Y.) NOV 2001, vol. 25, no. 3, November 2001 (2001-11-01), pages 201 - 209, XP009045307, ISSN: 0741-8329 *
DATABASE EMBL [online] 1 March 2004 (2004-03-01), GALAGAN ET AL., XP002321308, retrieved from EBI Database accession no. Q7RYN4 *
DATABASE EMBL [online] 1 October 2003 (2003-10-01), GLOECKNER ET AL., XP002321307, retrieved from EBI Database accession no. Q7USF5 *
DATABASE EPO PROTEINS [online] 14 June 2002 (2002-06-14), CHAUDHARY ET AL., XP002321309, retrieved from EBI Database accession no. AX411500 *
DATABASE EPO PROTEINS [online] 26 October 2001 (2001-10-26), BEASLEY ET AL., XP002321311, retrieved from EBI Database accession no. AX256979 *
DATABASE GENESEQ [online] 12 February 2004 (2004-02-12), CHACONAS ET AL., XP002321310, retrieved from EBI Database accession no. ADF72653 *
JOUAULT T ET AL: "PEPTIDES THAT MIMIC CANDIDA ALBICANS-DERIVED BETA-1,2-LINKED MANNOSIDES", GLYCOBIOLOGY, IRL PRESS,, GB, vol. 11, no. 8, August 2001 (2001-08-01), pages 693 - 701, XP009026488, ISSN: 0959-6658 *
MIURA Y ET AL: "Peptides binding to a Gb3 mimic selected from a phage library", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1673, no. 3, 4 August 2004 (2004-08-04), pages 131 - 138, XP004523265, ISSN: 0304-4165 *
SANTAMARIA H ET AL: "Identification of peptide sequences specific for serum antibodies from human papillomavirus-infected patients using phage display libraries", CLINICAL IMMUNOLOGY (ORLANDO), vol. 101, no. 3, December 2001 (2001-12-01), pages 296 - 302, XP009045311, ISSN: 1521-6616 *

Also Published As

Publication number Publication date
WO2005098435A2 (en) 2005-10-20
EP1733231A2 (en) 2006-12-20
US8071552B2 (en) 2011-12-06
JP2007531536A (en) 2007-11-08
DE602005027830D1 (en) 2011-06-16
CA2560726A1 (en) 2005-10-20
EP1733231B1 (en) 2011-05-04
US20080039402A1 (en) 2008-02-14
ATE508362T1 (en) 2011-05-15
AU2005229779A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
DE602005027830D1 (en) PEPTIDES AND PEPTIDE MIMETICS BINDING TO CD23
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
García-Medel et al. Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to endoplasmic reticulum aminopeptidase 1 (ERAP1)
EP2226334A3 (en) Immunoregulatory structures from normally occuring proteins
RU2015103816A (en) CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E
AU2003239659A1 (en) Peptide epitopes common to antigens of the same multigene family
JP2015504052A5 (en)
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
WO2012126118A8 (en) Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
PT1587830E (en) Peptide inhibitors of toxins derived from ll-37
EA201100459A1 (en) COMPOSITIONS INCLUDING INTERLEUKIN-1 AND PEPTIDES
Marangoni et al. Unmasking Snake Venom of Bothrops leucurus: Purification and Pharmacological and Structural Characterization of New PLA2 Bleu TX‐III
Ueda et al. Ni (II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts
IL154102A0 (en) Urocortin proteins and uses thereof
BRPI0715331B8 (en) polypeptide comprising an n-terminal portion and a c-terminal portion, and use thereof
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
Chen et al. Fusion expression and purification of four disulfide-rich peptides reveals enterokinase secondary cleavage sites in animal toxins
Kowalska et al. Trypsin inhibitors from the garden four o’clock (Mirabilis jalapa) and spinach (Spinacia oleracea) seeds: isolation, characterization and chemical synthesis
WO2002061435A3 (en) Subunit vaccines with a2 supermotifs
TW200505943A (en) Polypeptide
Schafer et al. A highly specific system for efficient enzymatic removal of tags from recombinant proteins
HRP20190544T1 (en) CYCLIC ANALYSIS OF APELINES
EP1842911A4 (en) HLA-BINDING PEPTIDES, DNA FRAGMENTS ENCODING SUCH PEPTIDES AND RECOMBINANT VECTORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2560726

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005718527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007506867

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005229779

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005229779

Country of ref document: AU

Date of ref document: 20050405

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005229779

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005718527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10594674

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10594674

Country of ref document: US